MLL translocation in two castration-resistant prostate cancer patients

被引：0

作者：

Chowdry, Rajasree Pia ^{[1
]}

Ledet, Elisa ^{[2
]}

Asinghe, Lahiru Ran. ^{[3
]}

Sartor, Alton Oliver ^{[2
]}

机构：

[1] Tulane Univ, Sect Hematol Med Oncol, Hematol Oncol, New Orleans, LA USA

[2] Tulane Canc Ctr, Dept Urol, New Orleans, LA USA

[3] Tulane Univ, Sch Med, New Orleans, LA 70112 USA

来源：

CANADIAN JOURNAL OF UROLOGY | 2016年 / 23卷 / 05期

关键词：

prostate cancer; castration-resistant; MLL; bone marrow; FUSION PROTEINS; MENIN; LEUKEMIA;

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The mixed-lineage leukemia (MLL) protein acts as a histone methyltransferase regulating multiple genetic elements. Rearrangements of the MLL gene result in expression of MLL fusion proteins that occur in some acute leukemias and are associated with poor prognosis. The MLL protein complex has been shown to interact with the androgen receptor via the MLL-menin subunit, thus promoting gene activation. The presence of MLL translocation has not been previously reported in patients with castrate resistant prostate cancer (CRPC). We describe two cases of metastatic CRPC with a translocation in the MLL gene detected by a specific fluorescent in situ hybridization (FISH) assay. Both patients had an aggressive course and succumbed to the illness.

引用

页码：8483 / 8486

页数：4

共 50 条

[31] Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer [J].

Tsao, Che-Kai ;

Seng, Sonia ;

Oh, William K. ;

Galsky, Matthew D. .

CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 :163-169

[32] Novel approaches and future directions in castration-resistant prostate cancer [J].

Nabhan, C. ;

Parsons, B. ;

Touloukian, E. Z. ;

Stadler, W. M. .

ANNALS OF ONCOLOGY, 2011, 22 (09) :1948-1957

[33] New and emerging agents for the treatment of castration-resistant prostate cancer [J].

Higano, Celestia S. ;

Crawford, E. David .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (06) :S1-S8

[34] Darolutamide in hormone-sensitive and castration-resistant prostate cancer [J].

Palmieri, Valeria Emma ;

Roviello, Giandomenico ;

D'Angelo, Alberto ;

Casadei, Chiara ;

De Giorgi, Ugo ;

Giorgione, Roberta .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (05) :535-544

[35] Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy [J].

Gartrell, Benjamin A. ;

Saad, Fred .

THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (04) :194-202

[36] Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents [J].

Starosta, Sarah Bennett ;

Savage, Stephen J. .

CURRENT UROLOGY REPORTS, 2018, 19 (09)

[37] Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer [J].

Omlin, A. ;

Gillessen, S. .

UROLOGE, 2012, 51 (01) :8-+

[38] Neuroendocrine differentiation in castration-resistant prostate cancer: A case report [J].

Priftakis, Dimitrios ;

Kritikos, Nikolaos ;

Stavrinides, Stavros ;

Kleanthous, Stefanos ;

Baziotis, Nikolaos .

MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (06) :1392-1394

[39] Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer [J].

Sonpavde, Guru ;

Madan, Ankit ;

Baker, Mary K. ;

May, Jori E. ;

Naik, Gurudatta ;

Bae, Sejong .

CLINICAL GENITOURINARY CANCER, 2017, 15 (05) :534-539

[40] Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents [J].

Sarah Bennett Starosta ;

Stephen J. Savage .

Current Urology Reports, 2018, 19

← 1 2 3 4 5 →